NZ537458A - Means and methods for treatment evaluation - Google Patents

Means and methods for treatment evaluation

Info

Publication number: NZ537458A
Authority: NZ; New Zealand
Prior art keywords: individual; sequence; tag; marker gene; sample
Prior art date: 2001-01-23

Application number

NZ537458A

Other languages

English (en)

Inventor

Der Kuyl Antoinette Cornel Van

Marion Cornelissen

Original Assignee

Primagen Holding B

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-23

Filing date

2002-01-23

Publication date

2007-02-23

2001-09-28 Priority claimed from EP01203703A external-priority patent/EP1298221A1/fr

2002-01-23 Application filed by Primagen Holding B filed Critical Primagen Holding B

2007-02-23 Publication of NZ537458A publication Critical patent/NZ537458A/en

Links

238000000034 method Methods 0.000 title claims abstract description 73
238000011282 treatment Methods 0.000 title claims abstract description 66
238000011156 evaluation Methods 0.000 title description 3
108090000623 proteins and genes Proteins 0.000 claims abstract description 131
230000014509 gene expression Effects 0.000 claims abstract description 111
239000003550 marker Substances 0.000 claims abstract description 81
210000004027 cell Anatomy 0.000 claims abstract description 45
108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 claims abstract description 42
210000004524 haematopoietic cell Anatomy 0.000 claims abstract description 17
102000001558 Sialic Acid Binding Ig-like Lectin 1 Human genes 0.000 claims abstract 9
230000033115 angiogenesis Effects 0.000 claims description 43
208000007766 Kaposi sarcoma Diseases 0.000 claims description 40
206010028980 Neoplasm Diseases 0.000 claims description 40
210000004881 tumor cell Anatomy 0.000 claims description 32
150000007523 nucleic acids Chemical class 0.000 claims description 24
210000004369 blood Anatomy 0.000 claims description 23
239000008280 blood Substances 0.000 claims description 23
108020004707 nucleic acids Proteins 0.000 claims description 23
102000039446 nucleic acids Human genes 0.000 claims description 23
238000001514 detection method Methods 0.000 claims description 22
230000008569 process Effects 0.000 claims description 18
102000004169 proteins and genes Human genes 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 15
229940079593 drug Drugs 0.000 claims description 12
238000009007 Diagnostic Kit Methods 0.000 claims description 10
230000002491 angiogenic effect Effects 0.000 claims description 10
210000004204 blood vessel Anatomy 0.000 claims description 10
-1 Anti-VEGF RhuMAb Chemical compound 0.000 claims description 8
230000000977 initiatory effect Effects 0.000 claims description 6
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 4
229950010895 midostaurin Drugs 0.000 claims description 4
229950003608 prinomastat Drugs 0.000 claims description 4
YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 claims description 4
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 4
229960005314 suramin Drugs 0.000 claims description 4
230000015556 catabolic process Effects 0.000 claims description 3
238000002405 diagnostic procedure Methods 0.000 claims description 3
238000012423 maintenance Methods 0.000 claims description 3
WORSVFBVUCBRIP-VNQPRFMTSA-N (2r,3s)-n-[(2s)-3,3-dimethyl-1-oxo-1-(pyridin-2-ylamino)butan-2-yl]-n'-hydroxy-3-methoxy-2-(2-methylpropyl)butanediamide Chemical compound ONC(=O)[C@@H](OC)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)(C)C)C(=O)NC1=CC=CC=N1 WORSVFBVUCBRIP-VNQPRFMTSA-N 0.000 claims description 2
GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims description 2
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 2
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 claims description 2
NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
102400000068 Angiostatin Human genes 0.000 claims description 2
108010079709 Angiostatins Proteins 0.000 claims description 2
108090000644 Angiozyme Proteins 0.000 claims description 2
HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 claims description 2
102400001047 Endostatin Human genes 0.000 claims description 2
108010079505 Endostatins Proteins 0.000 claims description 2
108010066792 FCE 26644 Proteins 0.000 claims description 2
102000006992 Interferon-alpha Human genes 0.000 claims description 2
108010047761 Interferon-alpha Proteins 0.000 claims description 2
102000013462 Interleukin-12 Human genes 0.000 claims description 2
108010065805 Interleukin-12 Proteins 0.000 claims description 2
239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 claims description 2
108010016076 Octreotide Proteins 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims description 2
UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims description 2
DNUXJWBKTMJNEP-JVSLBXKQSA-N [(2R)-3-[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(2R,3R,4R,5R)-2-acetamido-4-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5,6-dihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]([C@@H](NC(C)=O)C=O)[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@H](O)CO)C(N)=O)OC(=O)CCCCCCCCCCCCCCC DNUXJWBKTMJNEP-JVSLBXKQSA-N 0.000 claims description 2
229950010817 alvocidib Drugs 0.000 claims description 2
BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims description 2
229940059720 apra Drugs 0.000 claims description 2
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
SMDHCQAYESWHAE-UHFFFAOYSA-N benfluralin Chemical compound CCCCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O SMDHCQAYESWHAE-UHFFFAOYSA-N 0.000 claims description 2
WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 claims description 2
ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 claims description 2
229950009003 cilengitide Drugs 0.000 claims description 2
AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims description 2
229960005537 combretastatin A-4 Drugs 0.000 claims description 2
HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 claims description 2
108700042119 disaccharide tripeptide Proteins 0.000 claims description 2
239000003596 drug target Substances 0.000 claims description 2
229940045109 genistein Drugs 0.000 claims description 2
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 2
235000006539 genistein Nutrition 0.000 claims description 2
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 2
229940094952 green tea extract Drugs 0.000 claims description 2
235000020688 green tea extract Nutrition 0.000 claims description 2
229940117681 interleukin-12 Drugs 0.000 claims description 2
229940084651 iressa Drugs 0.000 claims description 2
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 2
229950008959 marimastat Drugs 0.000 claims description 2
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 claims description 2
229960002700 octreotide Drugs 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
229960001639 penicillamine Drugs 0.000 claims description 2
229940109328 photofrin Drugs 0.000 claims description 2
UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 2
229940002612 prodrug Drugs 0.000 claims description 2
239000000651 prodrug Substances 0.000 claims description 2
WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 2
229950009136 solimastat Drugs 0.000 claims description 2
229950001248 squalamine Drugs 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
XUWLTCQVQARIFB-UHFFFAOYSA-J tetrasodium;7-[[4-[[4-[[5-[[5-[(6,8-disulfonatonaphthalen-2-yl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]carbamoylamino]-1-methylpyrrole-2-carbonyl]amino]-1-methylpyrrole-2-carbonyl]amino]naphthalene-1,3-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=CC(NC(=O)C3=CC(=CN3C)NC(=O)C3=CC(NC(=O)NC4=CN(C)C(C(=O)NC5=CN(C)C(C(=O)NC=6C=C7C(=CC(=CC7=CC=6)S([O-])(=O)=O)S([O-])(=O)=O)=C5)=C4)=CN3C)=CC=C21 XUWLTCQVQARIFB-UHFFFAOYSA-J 0.000 claims description 2
CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims description 2
229960003433 thalidomide Drugs 0.000 claims description 2
229950000578 vatalanib Drugs 0.000 claims description 2
YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 2
238000009482 thermal adhesion granulation Methods 0.000 description 81
239000000047 product Substances 0.000 description 57
108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
238000003757 reverse transcription PCR Methods 0.000 description 34
102100032855 Sialoadhesin Human genes 0.000 description 33
238000006243 chemical reaction Methods 0.000 description 23
239000000203 mixture Substances 0.000 description 22
238000003196 serial analysis of gene expression Methods 0.000 description 20
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 19
210000001519 tissue Anatomy 0.000 description 15
239000012634 fragment Substances 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
238000010790 dilution Methods 0.000 description 13
239000012895 dilution Substances 0.000 description 13
238000012790 confirmation Methods 0.000 description 12
238000007857 nested PCR Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
102000016911 Deoxyribonucleases Human genes 0.000 description 10
108010053770 Deoxyribonucleases Proteins 0.000 description 10
238000001574 biopsy Methods 0.000 description 10
239000000872 buffer Substances 0.000 description 10
102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 9
108010066321 Keratin-14 Proteins 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
230000000694 effects Effects 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 8
108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 8
230000003321 amplification Effects 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
230000003902 lesion Effects 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
102000044465 Galectin-7 Human genes 0.000 description 7
101000608772 Homo sapiens Galectin-7 Proteins 0.000 description 7
230000000295 complement effect Effects 0.000 description 7
238000010839 reverse transcription Methods 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 5
108091033380 Coding strand Proteins 0.000 description 5
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 5
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 5
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 5
238000002123 RNA extraction Methods 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
108060002566 ephrin Proteins 0.000 description 5
102000012803 ephrin Human genes 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000003827 upregulation Effects 0.000 description 5
102000029792 Desmoplakin Human genes 0.000 description 4
108091000074 Desmoplakin Proteins 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
230000004075 alteration Effects 0.000 description 4
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 4
230000008859 change Effects 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
208000029078 coronary artery disease Diseases 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
208000019622 heart disease Diseases 0.000 description 4
238000011534 incubation Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
229940030793 psoriasin Drugs 0.000 description 4
230000004044 response Effects 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 3
102000004237 Decorin Human genes 0.000 description 3
108090000738 Decorin Proteins 0.000 description 3
102100033919 Ephrin-A2 Human genes 0.000 description 3
108010043942 Ephrin-A2 Proteins 0.000 description 3
101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 3
102000016769 Sorting nexin-17 Human genes 0.000 description 3
108050006340 Sorting nexin-17 Proteins 0.000 description 3
102000008864 Translin Human genes 0.000 description 3
108050009189 Translin Proteins 0.000 description 3
230000001772 anti-angiogenic effect Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000010410 layer Substances 0.000 description 3
230000037311 normal skin Effects 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
231100000444 skin lesion Toxicity 0.000 description 3
206010040882 skin lesion Diseases 0.000 description 3
238000012546 transfer Methods 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000007260 Deoxyribonuclease I Human genes 0.000 description 2
108010008532 Deoxyribonuclease I Proteins 0.000 description 2
102000010776 Dual Specificity Phosphatase 3 Human genes 0.000 description 2
108010038536 Dual Specificity Phosphatase 3 Proteins 0.000 description 2
102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 2
108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 2
101000806511 Homo sapiens Protein DEPP1 Proteins 0.000 description 2
101000801114 Homo sapiens Transmembrane protein 134 Proteins 0.000 description 2
102000019223 Interleukin-1 receptor Human genes 0.000 description 2
108050006617 Interleukin-1 receptor Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
102100037469 Protein DEPP1 Human genes 0.000 description 2
102100033701 Transmembrane protein 134 Human genes 0.000 description 2
238000000137 annealing Methods 0.000 description 2
230000003527 anti-angiogenesis Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
210000003989 endothelium vascular Anatomy 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
230000035876 healing Effects 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
238000010841 mRNA extraction Methods 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
101150072531 10 gene Proteins 0.000 description 1
101150066838 12 gene Proteins 0.000 description 1
101150025032 13 gene Proteins 0.000 description 1
101150082072 14 gene Proteins 0.000 description 1
101150078635 18 gene Proteins 0.000 description 1
102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
101100456831 Caenorhabditis elegans sams-5 gene Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010055196 EphA2 Receptor Proteins 0.000 description 1
102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241001268311 Icta Species 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
206010054107 Nodule Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000011225 antiretroviral therapy Methods 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
229960001936 indinavir Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229960001627 lamivudine Drugs 0.000 description 1
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000011886 postmortem examination Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
210000003065 pyriform sinus Anatomy 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
210000002105 tongue Anatomy 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NZ537458A 2001-01-23 2002-01-23 Means and methods for treatment evaluation NZ537458A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP01200228		2001-01-23
US32572201P	2001-09-28	2001-09-28
EP01203703A EP1298221A1 (fr)	2001-09-28	2001-09-28	Moyens et méthodes pour l'évaluation d'un traitement

Publications (1)

Publication Number	Publication Date
NZ537458A true NZ537458A (en)	2007-02-23

Family

ID=27224257

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NZ537458A NZ537458A (en)	2001-01-23	2002-01-23	Means and methods for treatment evaluation
NZ526924A NZ526924A (en)	2001-01-23	2002-01-23	Means and methods for treatment evaluation

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NZ526924A NZ526924A (en)	2001-01-23	2002-01-23	Means and methods for treatment evaluation

Country Status (4)

Country	Link
JP (1)	JP2004523232A (fr)
CA (1)	CA2369183A1 (fr)
NZ (2)	NZ537458A (fr)
WO (1)	WO2002059558A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2397971T3 (es) *	2006-06-02	2013-03-12	Pfizer Products Incorporated	Ensayo de células tumorales circulantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5470824A (en) *	1991-05-31	1995-11-28	The Regents Of The University Of California	Method to treat Kaposi's sarcoma
US5827658A (en) *	1996-08-09	1998-10-27	The United States Of America As Reprsented By The Department Of Health And Human Services	Isolation of amplified genes via cDNA subtractive hybridization
US5858715A (en) *	1997-01-29	1999-01-12	Incyte Pharmaceuticals, Inc.	Human apoptosis-associated protein
AU7499198A (en) *	1997-05-21	1998-12-11	Johns Hopkins University, The	Gene expression profiles in normal and cancer cells
AU1853600A (en) *	1999-01-06	2000-07-24	Choong-Chin Liew	Method for the detection of gene transcripts in blood and uses thereof
US6436642B1 (en) *	1999-04-20	2002-08-20	Curagen Corporation	Method of classifying a thyroid carcinoma using differential gene expression
ATE324877T1 (de) *	1999-08-17	2006-06-15	Purdue Research Foundation	Behandlung von metastatischer krankheit

2002
- 2002-01-23 JP JP2002559626A patent/JP2004523232A/ja active Pending
- 2002-01-23 NZ NZ537458A patent/NZ537458A/en unknown
- 2002-01-23 WO PCT/NL2002/000051 patent/WO2002059558A2/fr not_active Ceased
- 2002-01-23 CA CA002369183A patent/CA2369183A1/fr not_active Abandoned
- 2002-01-23 NZ NZ526924A patent/NZ526924A/en unknown

Also Published As

Publication number	Publication date
CA2369183A1 (fr)	2002-07-23
WO2002059558A3 (fr)	2003-01-09
WO2002059558A8 (fr)	2003-11-06
NZ526924A (en)	2005-09-30
WO2002059558A2 (fr)	2002-08-01
JP2004523232A (ja)	2004-08-05

Publication	Publication Date	Title
JP2009539404A (ja)	2009-11-19	大腸癌の早期検出および予後のためのメチル化マーカー
US20080254457A1 (en)	2008-10-16	Methods for Evaluating Drug-Resistance Gene Expression in the Cancer Patient
US20090215709A1 (en)	2009-08-27	Methylation markers for diagnosis and treatment of cancers
JPH11503924A (ja)	1999-04-06	ヒトｂｒｃａ１遺伝子のコード配列
KR102029775B1 (ko)	2019-10-08	비근침윤성 방광암 진단용 바이오마커 및 이의 용도
US20090098563A1 (en)	2009-04-16	Diagnosis of (a risk of) disease and monitoring of therapy
Oba-Shinjo et al.	2005	Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference analysis
JP2005522224A (ja)	2005-07-28	Ｄｎａの高メチル化と遺伝子サイレンシングの両方をスクリーニングするためのｅｃｉｓｔマイクロアレイと、そのｅｃｉｓｔマイクロアレイを利用して遺伝子の発現、ｄｎａのメチル化、ヒストンのアセチル化を評価するための統合システム
Scurto et al.	1998	A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia
Fan et al.	2004	Expression patterns of cell cycle and apoptosis‐related genes in a multidrug‐resistant human colon carcinoma cell line
EP1725679B1 (fr)	2009-06-03	Procédé de suivi de thérapie des tumeurs utilisant AC133 mRNA
EP3390661B1 (fr)	2022-05-04	Utilisation d'arn antisens longs non-codants pour le diagnostic du cancer de la prostate
US20030219772A1 (en)	2003-11-27	Means and methods for treatment evaluation
US20030170720A1 (en)	2003-09-11	Means and methods for treatment evaluation
EP1225233A2 (fr)	2002-07-24	Moyens et méthodes pour l'évaluation d'un traitement
NZ537458A (en)	2007-02-23	Means and methods for treatment evaluation
US20070207511A1 (en)	2007-09-06	Methods for identification, assessment, prevention, and therapy of cancer
Wei et al.	2001	Relationship between structure and function of JWA in the modulation of cell differentiation
AU689840B2 (en)	1998-04-09	Association of kinesin with sensitivity to chemotherapeutic drugs
CA2163249A1 (fr)	1994-12-08	Bc200 rna; sondes pour ces sequences et leur utilisation
LIU et al.	1999	Screening of Specific Changes in mRNAs in Thyroid Tumors by Sequence Specific Differential Display Decreased Expression of c-fos mRNA in Papillary Carcinoma
US8206920B2 (en)	2012-06-26	Diagnostic assay for the specific treatment of acute myeloid leukemia
EP1298221A1 (fr)	2003-04-02	Moyens et méthodes pour l'évaluation d'un traitement
CN119317724A (zh)	2025-01-14	一种利用数字pcr的癌症患者定制型癌症治疗方法
AU2002228477A1 (en)	2002-08-06	Means and methods for treatment evaluation

Legal Events

Date	Code	Title	Description
2007-06-29	PSEA	Patent sealed